Safety Shot supplement shown to reduce alcohol effects

SCOTTSDALE, Ariz. - Safety Shot, Inc. (NASDAQ:SHOT), a company specializing in wellness and dietary supplements, has announced the publication of a clinical trial demonstrating the effectiveness of its product, Safety Shot®, in reducing the impact of alcohol consumption. The study, appearing in the Journal of Nutrition and Dietary Supplements on February 26, 2025, provides evidence that Safety Shot® can significantly lower blood and breath alcohol concentrations and alleviate hangover symptoms. The company, currently valued at $32.63 million, has shown strong revenue growth of 112.79% over the last twelve months, according to InvestingPro data.

The randomized, double-blind, placebo-controlled trial, conducted by The Center for Applied Health Sciences (CAHS), involved participants of various demographics who consumed alcohol followed by either Safety Shot® or a placebo. The results showed that Safety Shot® could reduce blood alcohol levels within 30 minutes, increase aldehyde dehydrogenase—a key enzyme in metabolizing alcohol—and enhance urine output, indicating improved elimination of alcohol from the body.

Participants also reported experiencing less head discomfort, fatigue, and improved energy and concentration after taking Safety Shot®. These findings suggest that Safety Shot® could be a beneficial supplement for individuals consuming alcohol, providing a faster metabolic response to eliminate alcohol and its toxic intermediates.

The study’s design aimed to mimic real-world conditions as closely as possible, without being limited to specific demographics, to ensure broad applicability of the results. Despite the small amount of alcohol permitted due to ethical and legal constraints, the trial outcomes indicate that Safety Shot® may offer a new solution for managing the after-effects of drinking.

Safety Shot, Inc. CEO Jarrett Boon expressed optimism about the product’s potential role in daily practice, given the peer-reviewed evidence of its efficacy. Dr. Tim Ziegenfuss, CEO of CAHS, also highlighted the supplement’s potential in supporting better outcomes post-alcohol consumption.

As Safety Shot® enters the growing market for hangover cure products, which is expected to reach over $6 billion by 2032, the company is positioned to capitalize on the demand for effective solutions to the negative health consequences of hangovers. InvestingPro analysis indicates the stock has seen a notable 9.74% return over the past week, with analysts forecasting sales growth of 188.96% for the current year. According to InvestingPro’s Fair Value analysis, the stock currently appears to be fairly valued. For deeper insights into Safety Shot’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.

Safety Shot® is a proprietary blend of natural ingredients designed to support the body’s natural detoxification processes and promote overall wellness. It is available for purchase online and is being introduced to distributors, retailers, restaurants, and bars throughout 2025. The company maintains a healthy current ratio of 1.9, indicating strong short-term liquidity, though InvestingPro data shows an overall financial health score of 1.41, suggesting room for improvement. InvestingPro subscribers have access to 14 additional key insights about Safety Shot’s financial position and market performance.

This news is based on a press release statement from Safety Shot, Inc.

In other recent news, Scandic Hotels Group reported a strong fourth quarter for 2024, showcasing significant improvements in its financial metrics. The company achieved an adjusted EBITDA of SEK 544 million, up from SEK 451 million in the previous year, with an EBITDA margin increase to 9.9% from 8.3%. Scandic also reduced its net debt to SEK 128 million, reflecting robust financial management. The company announced a strategic partnership with SAS and plans for tech upgrades, alongside a proposed ordinary dividend of 2.6 SEK per share and a SEK 500 million share buyback program. Meanwhile, Safety Shot, Inc. secured $1 million in funding through a Securities Purchase Agreement with an accredited investor. This deal involves the issuance of 2,222,222 shares at $0.45 per share, aimed at strengthening the company’s financial position for ongoing operations and potential expansion. These developments highlight the companies’ strategic moves to bolster their financial health and market positions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.